Special Access for the Use of Voclosporin for Kidney Transplantation
Weill Medical College of Cornell University
Voclosporin is an investigational medication previously studied to prevent acute rejection in
patients who receive a kidney transplant. This study is a compassionate release program where
subjects previously participating in the study entitled A Phase 2B, Randomized, Multicenter,
Open-Label, Concentration Controlled, Safety Study of ISA247 and Tacrolimus (Prograf®) in
denovo Renal Transplant Patients (ISA05-01)" may be eligible to continue to receive
voclosporin despite the Phase 2B study being terminated by the sponsor. Under the
compassionate release program, subjects previously taking voclosporin may continue to receive
the study medication until the drug is FDA-approved and commercially available in the United
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.